Payment overview · 2025
General Payments
$204.08
10 reported records · 7 companies
Healthcare provider profile · identity verified
Joseph W Luinstra, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEWTON, KS · NPI 1356378236
Verified facts
What the public records show
CMS Open Payments records show Joseph W Luinstra, MD received $204.08 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.75 | 25.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.45 | 22.3% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $27.84 | 13.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.77 | 11.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.15 | 10.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.71 | 8.7% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $14.41 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $204.08 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.75 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.45 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
186 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
107 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 422 | 110 |
| Omeprazole | Omeprazole | 400 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 348 | 95 |
| Losartan Potassium | Losartan Potassium | 280 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 269 | 62 |
| Metformin Hcl | Metformin Hcl | 248 | 70 |
| Simvastatin | Simvastatin | 228 | 62 |
| Lisinopril | Lisinopril | 223 | 66 |
| Xarelto | Rivaroxaban | 202 | 53 |
| Jardiance | Empagliflozin | 186 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 49 |
| Furosemide | Furosemide | 153 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 139 | 33 |
| Tramadol Hcl | Tramadol Hcl | 136 | 19 |
| Meloxicam | Meloxicam | 134 | 39 |
| Potassium Chloride | Potassium Chloride | 131 | 32 |
| Gabapentin | Gabapentin | 129 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 35 |
| Cephalexin | Cephalexin | 107 | 79 |
| Trulicity | Dulaglutide | 107 | 18 |
| Allopurinol | Allopurinol | 103 | 28 |
| Prednisone | Prednisone | 101 | 74 |
| Ozempic | Semaglutide | 98 | 16 |
| Azithromycin | Azithromycin | 96 | 73 |
| Trazodone Hcl | Trazodone Hcl | 92 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 22 |
| Atenolol | Atenolol | 83 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | suppressed |
| Carvedilol | Carvedilol | 78 | 15 |
| Linzess | Linaclotide | 73 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 34 |
| Finasteride | Finasteride | 70 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 20 |
| Januvia | Sitagliptin Phosphate | 64 | 16 |
| Lovastatin | Lovastatin | 63 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 13 |
| Mounjaro | Tirzepatide | 59 | suppressed |
| Amoxicillin | Amoxicillin | 58 | 41 |
| Eliquis | Apixaban | 56 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 15 |
| Sertraline Hcl | Sertraline Hcl | 49 | 13 |
| Chlorthalidone | Chlorthalidone | 47 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 46 | suppressed |
| Mupirocin | Mupirocin | 45 | 30 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Famotidine | Famotidine | 38 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 12 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 23 |
| Diazepam | Diazepam | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 29 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Invokana | Canagliflozin | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 25 | 23 |
| Aimovig Autoinjector | Erenumab-Aooe | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 18 |
| Mirtazapine | Mirtazapine | 21 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 20 |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $204.08 · 10 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, BEYFORTUS, COMIRNATY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, Kerendia, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, XPOVIO, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error